- Home
- BIVI vs SACH Comparison
BIVI vs SACH Comparison
Compare BIVI & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- SACH
- Stock Information
- Founded
- BIVI 2013
- SACH 2010
- Country
- BIVI United States
- SACH United States
- Employees
- BIVI 14
- SACH N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- SACH Real Estate Investment Trusts
- Sector
- BIVI Health Care
- SACH Real Estate
- Exchange
- BIVI Nasdaq
- SACH Nasdaq
- Market Cap
- BIVI 18.8M
- SACH 50.7M
- IPO Year
- BIVI N/A
- SACH 2017
- Fundamental
- Price
- BIVI $1.02
- SACH $1.27
- Analyst Decision
- BIVI Strong Buy
- SACH Buy
- Analyst Count
- BIVI 1
- SACH 2
- Target Price
- BIVI $30.00
- SACH $2.25
- AVG Volume (30 Days)
- BIVI 297.1K
- SACH 357.1K
- Earning Date
- BIVI 05-13-2025
- SACH 05-09-2025
- Dividend Yield
- BIVI N/A
- SACH 14.23%
- EPS Growth
- BIVI N/A
- SACH N/A
- EPS
- BIVI N/A
- SACH N/A
- Revenue
- BIVI N/A
- SACH $10,951,064.00
- Revenue This Year
- BIVI N/A
- SACH N/A
- Revenue Next Year
- BIVI N/A
- SACH N/A
- P/E Ratio
- BIVI N/A
- SACH N/A
- Revenue Growth
- BIVI N/A
- SACH N/A
- 52 Week Low
- BIVI $0.99
- SACH $1.00
- 52 Week High
- BIVI $7.50
- SACH $4.64
- Technical
- Relative Strength Index (RSI)
- BIVI 23.10
- SACH 58.40
- Support Level
- BIVI $1.09
- SACH $1.01
- Resistance Level
- BIVI $1.24
- SACH $1.34
- Average True Range (ATR)
- BIVI 0.10
- SACH 0.07
- MACD
- BIVI -0.01
- SACH 0.03
- Stochastic Oscillator
- BIVI 6.67
- SACH 78.79
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About SACH Sachem Capital Corp.
Sachem Capital Corp is a United States-based real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.